TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
1-Year Return
35.44%
This Quarter Return
+25.92%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$269M
AUM Growth
-$59.6M
(-18%)
Cap. Flow
-$73.8M
Cap. Flow
% of AUM
-27.47%
Top 10 Holdings %
Top 10 Hldgs %
55.73%
Holding
84
New
36
Increased
10
Reduced
12
Closed
25
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$21.1M |
| 2 |
Medtronic
MDT
|
$14.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$8.66M |
| 4 |
Legend Biotech
LEGN
|
$8.06M |
| 5 |
DexCom
DXCM
|
$6.66M |
Top Sells
| 1 |
Abbott
ABT
|
$17.7M |
| 2 |
Tandem Diabetes Care
TNDM
|
$17M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$16.3M |
| 4 |
ARK Innovation ETF
ARKK
|
$14.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
$12.3M |
Sector Composition
| 1 | Healthcare | 99.2% |
| 2 | Financials | 0.24% |
| 3 | Industrials | 0.21% |
| 4 | Energy | 0.12% |
| 5 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Berkshire Hathaway Class B
BRK.B
$1.09T
| $201K | 0.07% |
+588
| New | +$201K |
|
52
Kinder Morgan
KMI
$59.4B
| $178K | 0.07% |
+10,324
| New | +$178K |
|
53
Antero Midstream
AM
$8.65B
| $135K | 0.05% |
11,675
+561
| +5% | +$6.51K |
|
54
Rithm Capital
RITM
$6.66B
| $127K | 0.05% |
+13,531
| New | +$127K |
|
55
JetBlue
JBLU
$1.85B
| $123K | 0.05% |
+13,891
| New | +$123K |
|
56
Viatris
VTRS
$12B
| $104K | 0.04% |
+10,379
| New | +$104K |
|
57
Under Armour Class C
UA
$2.19B
| $77.9K | 0.03% |
+11,603
| New | +$77.9K |
|
58
Femasys
FEMY
$12M
| $57K | 0.02% |
111,706
-14,776
| -12% | -$7.54K |
|
59
AbbVie
ABBV
$376B
| – | – |
-49,213
| Closed | -$7.84M |
|
|
60
Abbott
ABT
$231B
| – | – |
-174,802
| Closed | -$17.7M |
|
61
Akero Therapeutics
AKRO
$3.52B
| – | – |
-88,524
| Closed | -$3.39M |
|
62
Altimmune
ALT
$314M
| – | – |
-528,814
| Closed | -$2.23M |
|
63
Apellis Pharmaceuticals
APLS
$3.62B
| – | – |
-77,048
| Closed | -$5.08M |
|
|
64
ARK Innovation ETF
ARKK
$7.46B
| – | – |
-350,000
| Closed | -$14.1M |
|
65
Beam Therapeutics
BEAM
$1.88B
| – | – |
-107,230
| Closed | -$3.28M |
|
66
BioMarin Pharmaceuticals
BMRN
$10.9B
| – | – |
-76,070
| Closed | -$7.4M |
|
67
B2Gold
BTG
$5.34B
| – | – |
-19,076
| Closed | -$75.2K |
|
68
Evolus
EOLS
$486M
| – | – |
-160,269
| Closed | -$1.36M |
|
69
Evolent Health
EVH
$1.1B
| – | – |
-268,011
| Closed | -$8.7M |
|
70
FibroGen
FGEN
$45.7M
| – | – |
0
| – | – |
|
71
Guardant Health
GH
$7.65B
| – | – |
-255,011
| Closed | -$5.98M |
|
72
uniQure
QURE
$973M
| – | – |
-227,273
| Closed | -$4.58M |
|
|
73
Sarepta Therapeutics
SRPT
$1.93B
| – | – |
-88,961
| Closed | -$12.3M |
|
74
Thermo Fisher Scientific
TMO
$185B
| – | – |
-15,889
| Closed | -$9.16M |
|
|
75
Tandem Diabetes Care
TNDM
$837M
| – | – |
-417,448
| Closed | -$17M |
|